How the Revised EU Pharmaceutical Framework Supports Innovation

The EU pharmaceutical legislation reform represents the most significant overhaul of the European medicines framework in more than two decades. Following political agreement in December 2025, the package is expected to modernise how medicines are developed, authorised and supported across the European Union.

This article explores how the revised framework may support pharmaceutical innovation through regulatory sandboxes, enhanced opportunities for early regulatory engagement, and updated incentive mechanisms. It also considers the role of existing initiatives, such as the EMA’s PRIME scheme and Scientific Advice, within this evolving regulatory landscape, while highlighting key considerations for companies as implementing measures and regulatory guidance continue to evolve.

What the revised EU pharmaceutical framework means for pharmaceutical innovation

The revised European Union (EU) pharmaceutical framework represents the most significant reform of European medicines legislation in more than two decades. Beyond changes to regulatory protection periods and incentives, the package introduces new mechanisms to foster pharmaceutical innovation, encourage earlier regulatory engagement and strengthen the regulatory environment supporting pharmaceutical research and development.

Among the most notable developments are the establishment of a legal framework for regulatory sandboxes, the reinforcement of initiatives such as the European Medicines Agency’s (EMA) PRIority MEdicines (PRIME) scheme, and a revised system of incentives designed to encourage the development of innovative medicines in areas of high public health need. Overall, these measures seek to balance innovation, regulatory rigour and patient access within an increasingly complex scientific and technological landscape.

For pharmaceutical and biotechnology companies, these reforms are significant not only because they alter the incentive framework for medicine development, but also because they create new opportunities for earlier regulatory engagement and more tailored approaches to addressing novel scientific challenges. Understanding how these mechanisms develop in practice will be an important part of future regulatory strategy within the European Union.

Regulatory sandboxes: controlled flexibility for innovation

Regulatory sandboxes are among the most visible mechanisms supporting regulatory and technological innovation in the revised EU pharmaceutical framework. Rather than a general waiver from existing rules, they aim to provide a controlled, time-limited environment in which innovative medicinal products, technologies, and methodologies can be developed, tested, or validated under regulatory supervision when existing frameworks do not fully address novel scientific or technical challenges. The diagram below provides an overview of the lifecycle of a proposed regulatory sandbox.

Illustrative schematic of the regulatory sandbox lifecycle adapted from the original EMA concept. It shows decision logic, sandbox progression (from R&D to access), risk-based termination, and the system-level feedback loop in which sandbox learnings inform potential future adaptations of the regulatory framework. (Adapted from European Commission (2026). Regulatory sandboxes – Pharmaceutical Committee (Agenda item 3b1).); B/R = Benefit–risk evaluation; CHMP = Committee for Medicinal Products for Human Use; COM = European Commission; EMA = European Medicines Agency; MA = Marketing Authorisation; R&D = Research and Development.

Importantly, regulatory sandboxes should not be understood as lowering standards for quality, safety or efficacy. Rather, they provide a structured framework in which regulators and developers can explore how specific scientific or regulatory challenges may be addressed while maintaining appropriate safeguards, regulatory oversight and the integrity of benefit-risk assessments.

This may be particularly relevant for areas such as digitalisation, artificial intelligence, novel manufacturing approaches, real-world evidence methodologies and complex product lifecycles, where conventional development or assessment pathways may not always provide a straightforward fit.

The revised framework provides a legal basis for regulatory sandboxes, with competent authorities retaining supervisory and corrective powers where necessary. Participants, including sponsors, marketing authorisation applicants and marketing authorisation holders, remain responsible for complying with applicable regulatory requirements. The practical governance, selection criteria and operation of sandboxes will continue to evolve through implementation, guidance and regulatory experience.

For developers, the practical value of a sandbox is therefore not that it relaxes evidentiary requirements, but that it may allow specific scientific or regulatory questions to be addressed within a defined, supervised and legally structured environment.

PRIME and the importance of early regulatory engagement

Since its launch in 2016, EMA’s PRIME scheme has supported the development of medicines that may address unmet medical needs through earlier and more proactive interaction between developers and regulators. The objective is to optimise development programmes, strengthen evidence generation, and support timely patient access when available data justify accelerated assessment.

The PRIME scheme originated as an EMA initiative, and the revised legislation, recognising the underlying principles of early regulatory engagement as a means of supporting the development of innovative medicines, brings this into a formal legislative footing.

In recent years, EMA has also piloted several operational enhancements, including expedited scientific advice, submission-readiness interactions, and a regulatory roadmap and development tracker tool intended to improve predictability and facilitate more coordinated regulatory engagement. The EMA will integrate all three features as permanent PRIME tools reflecting a broader shift towards a system that not only supports innovation but actively anticipates development challenges and facilitates more efficient regulatory decision-making.

The introduction of these tools coincides with the EMA’s preparations for the revised EU pharmaceutical legislation expected to come into effect in 2028. Once the new framework takes effect, PRIME will be formally embedded within the legislation.

For companies developing innovative medicines, particularly those involving novel technologies or complex development pathways, early regulatory engagement is becoming increasingly important for identifying potential challenges, aligning on evidence-generation strategies and supporting efficient development programmes.

Incentives for innovative medicines and priority public health needs

Innovative medicines

A key element of the revised pharmaceutical framework is the reform of regulatory incentives to support innovative medicines. The agreed reform package maintains 8 years of regulatory data protection (RDP) and reduces the baseline period of market protection from 2 years (currently) to 1 year; however, additional market protection may be available where specific conditions defined in the legislation are met, including:

• where a medicine addresses an unmet medical need,
• is a new active substance and uses a relevant and evidence-based comparator in accordance with EMA scientific advice, and meets specified criteria,
• or obtains approval for a new therapeutic indication that brings significant clinical benefit.

Depending on the circumstances, the combined period of protection may therefore be extended beyond the baseline framework.

This revised incentive model seeks to encourage pharmaceutical innovation through targeted regulatory incentives.

Orphan medicinal products

The revised framework also updates incentives for orphan medicinal products, aiming to encourage investment in rare diseases while focusing support on products that address significant unmet patient needs. It introduces a tiered approach to market exclusivity, replacing the current uniform 10-year period with a 9-year period, unless the product qualifies as breakthrough, in which case it will be eligible for 11 years, or if it is a bibliographic application, in which case it will be a 4-year period. Additional extensions may apply for authorised new orphan indications that meet the legislative criteria, subject to applicable caps. This tiered exclusivity model supports regulatory innovation by better targeting incentives towards medicines that address significant unmet needs.

Priority antimicrobials

The legislation introduces new incentives for priority antimicrobials to address antimicrobial resistance, including a transferable exclusivity voucher to stimulate investment where traditional commercial incentives may be insufficient. The voucher may provide an additional 12 months of regulatory data or market protection, which can be used for another centrally authorised product in the holder’s portfolio or transferred to another company. Eligibility is limited to priority antimicrobials demonstrating significant clinical benefit against antimicrobial resistance, with safeguards on transfer, timing of use, transparency regarding public funding, supply obligations, sales thresholds, and an overall cap on the number of vouchers.

Collectively, these measures demonstrate that the revised EU pharmaceutical framework extends beyond accelerating procedures. It also seeks to improve regulatory predictability, support innovation in medicine development, regulatory approaches and evidence generation, encourage investment in priority public health areas and facilitate patient access to medicines that address unmet needs.

Looking ahead

Although implementation will continue through formal adoption, transitional arrangements, implementing measures, and regulatory guidance, the overall direction is clear. The revised framework seeks to maintain the European Union’s high standards for quality, safety and efficacy while creating a more agile and innovation-supportive regulatory environment.

For pharmaceutical and biotechnology companies, the revised framework may create opportunities for earlier regulatory engagement, use of regulatory sandboxes and access to revised incentive structures, all of which can support more efficient development strategies. Their impact will depend on how regulators and developers apply the new mechanisms in practice. Companies that engage early and integrate these opportunities into their regulatory strategy are likely to be best placed to benefit from the revised framework.

Disclaimer: This article provides a high-level overview of selected elements of the revised EU pharmaceutical legislation and is intended for informational purposes only. Readers should consult the final adopted legal texts, implementing measures and regulatory guidance for complete requirements and applicable obligations.

Conclusion

The revised EU pharmaceutical framework signals a clear shift towards a more innovation-supportive regulatory environment while maintaining the EU’s established standards for quality, safety and efficacy. Regulatory sandboxes may provide a supervised environment to address novel scientific or technical challenges, while enhanced opportunities for earlier regulatory engagement and a revised incentive framework may support more efficient development planning and encourage investment in areas of high public health need.

For pharmaceutical and biotechnology companies, the challenge will be translating these policy changes into practical regulatory strategies. This includes understanding which measures are relevant to a specific product, when to seek early regulatory engagement, how to plan evidence generation and how to monitor the implementation of the final legislation, implementing measures and regulatory guidance.

DLRC can support pharmaceutical and biotechnology companies in navigating this evolving landscape through phase-appropriate regulatory strategy, scientific advice preparation, development planning, orphan and unmet medical need strategies, regulatory submissions and lifecycle support. As the revised framework continues to be implemented, early and informed regulatory planning will be key to making the best use of the opportunities it creates. Contact our experts at hello@dlrcgroup.com.